Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of relapse activity. This phenomenon, termed progression independent of relapse activity (PIRA), underscores that many patients continue to accumulate disability even when relapse rates are low. This shift has forced researchers to look at what is actually driving PIRA, and a major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions. These lesions are characterized by a smoldering inflammatory process that contributes to ongoing tissue damage and disability progression.
Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin, and support functional recovery. By targeting the underlying mechanism of myelin loss, Lucid-MS aims to address the progression that occurs independently of relapses, potentially offering a new approach to slowing disability accumulation in MS patients. This focus on myelin preservation and repair represents a departure from traditional immunomodulatory therapies, which primarily target the inflammatory component of the disease.
The importance of this approach is highlighted by the growing body of evidence linking chronic active lesions to disability progression. These lesions are often visible on MRI scans and are associated with a more aggressive disease course. By specifically targeting myelin degradation, Lucid-MS could potentially intervene in this process, offering hope for patients who continue to worsen despite treatment. The company’s commitment to this novel mechanism underscores the broader industry trend toward addressing the neurodegenerative aspects of MS, which are often the most debilitating for patients.
For more information on Quantum BioPharma and its pipeline, visit the company’s newsroom at https://ibn.fm/QNTM. The full terms of use and disclaimers applicable to all content provided by InvestorBrandNetwork can be found at http://IBN.fm/Disclaimer.
